OncoMatch/Clinical Trials/NCT06904196
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Is NCT06904196 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Lenvatinib plus SIRT and Lenvatinib for hepatocellular carcinoma non-resectable.
Treatment: Lenvatinib plus SIRT · Lenvatinib — This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hepatic arterial infusion chemotherapy
Patients who received prior hepatic arterial infusion chemotherapy (HAIC)
Cannot have received: radiotherapy
Patients who received prior radiotherapy
Cannot have received: systemic therapy
Patients who received prior systemic therapy, for HCC
Lab requirements
Blood counts
platelet count ≥50×10^9/L, leukocyte >3.0×10^9/L, Neutrophil count ≥1.5×10^9/L, haemoglobin ≥85 g/L
Kidney function
creatinine≤1.5×ULN
Liver function
ALT and AST≤5×ULN, albumin ≥28 g/L, total bilirubin ≤3× ULN, prolongation of prothrombin time ≤4 seconds
Adequate organ and hematologic function with platelet count ≥50×10^9/L, leukocyte >3.0×10^9/L, Neutrophil count ≥1.5×10^9/L, haemoglobin ≥85 g/L, ALT and AST≤5×ULN, albumin ≥28 g/L, total bilirubin ≤3× ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify